Indian Journal of Science and Technology

Open Access Open Access  Restricted Access Subscription Access

Increased Expression of PML Protein in Lymphocytes Induced by Serum from Patients with Severe Aplastic Anemia


Affiliations
1 Department of Developmental Biology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minamu-ku, Hiroshima, Japan
2 Department of Radiobiology, Institute for Environmental Sciences, Rokkasho , Aomori, Japan
3 Hiroshima Atomic Bomb Relief Foundation, Asakita-ku, Hiroshima, Japan
 

PML is essential for multiple apoptotic pathways and has an altered expression in human oncogenesis. However, the role of PML in regulating cell growth and apoptosis in aplastic anemia (AA) is still unclear. To investigate the involvement of PML in the pathogenesis of AA, the expression of PML protein and apoptosis in lymphocytes was measured with immunofluorescent staining after 24 hours incubation with serum of healthy individuals (controls, n=10) and patients with severe AA (SAA, n=10). After incubation with serum from SAA patients, PML protein was overexpressed both in peripheral lymphocytes from a normal donor and in a B cell line established from cells of the same individual. The normal lymphocytes contained a greater proportion of apoptotic cells after incubation with serum from SAA patients than serum from controls, which correlated to the serum-induced expression of PML. In addition, the induction of PML expression and apoptosis in lymphocytes by the serum was partly blocked by caspase 8 inhibitor, whereas no significant difference was found before and after caspase 3 inhibitor was added. These results indicate that some components contain of the serum of SAA patients, which was confirmed to γ-IFN by us, acts on lymphocytes not only to upregulate PML protein, but also to selectively activate caspase 8, causing apoptosis. This disregulation may play an important role in the pathogenesis of lymphocytopenia in aplastic anemia.

Keywords

Aplastic Anemia, PML Protein, Apoptosis, Caspase 3, Caspase 8
User

  • Berg JM (1990) Zinc fingers and other metal-binding domains: elements for interactions between macromolecules. J.Biol. Chem. 265, 6513-6516.

  • Callera F and Falcao RP (1997) Increased apoptosis cells in bone marrow biopsies from patients with aplastic anemia. Brit. J. Haematol. 8, 18-20.

  • Callera F, Garcia AB and Falcao RP (1998) Fas-mediated apoptosis with normal expression of bcl-2 and p53 in lymphocytes from aplastic anemia. Brit. J. Haematol.100, 698-703.

  • Camitta B, O’Reilly RJ, Sensenbrenner J, Rappeport J, Champlin R, Doney K, et al. (1983) Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood 62, 883-885.

  • Chan JY, Chin W, Liew CT, Chang KS and Johnson PJ (1998) Altered expression of the growth and transformation suppression PML gene in human hepatocellular carcinomas and in hepatitis tissues. Europ. J. Cancer 34, 1051-1022.

  • Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem.J. 326, 1-16.

  • Dai CH and Krantz S (1999) Interferon? induces upregulation and activation of caspases 1,3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood 93, 3309-3316.

  • Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M, et al. (1993) PML protein expression in hematopoitic and acute promyelocytic leukemia cells. Blood 82, 1858-1867.

  • de The H, Chomienne C, Lanotte M, Degos L and Dejean A (1990) The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347, 558-684.

  • de The H, Lavau C, Marchio A, Chomienne C, Degos L and Dejean A (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675-684.

  • Falcao RP, Voltarelli JC and Bottura C (1983) Some immunological studies in aplastic anemia. Journal of Clinical and Laboratory Immunology 10, 25-28.

  • Freemont PS, Hanson IM and Trousdale J (1991) A novel cysteine-rich sequence motif. Cell 64, 483-484.

  • Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leocini L, Bigerna B, et al. (1996) Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. American J. Pathol. 149, 2023-2035.

  • Goddard AD, Borrow J, Freemont PS and Solomon E (1991) Characterization of a zine finger gene disrupted by the t(15; 17) in acute promyelocytic leukemia. Science 254, 1371-1374.

  • Guiqnon F, Bels FD, Koken M, Feunteun J, Ameisen JC and de The H (1998) PML induces a novel caspase-independent death process. Nature Genet. 20, 259-264.

  • Hong Liu, Kimio Tanaka and Nanao Kamada (2008) Differential expression of PML in 60Co ?-ray and ?-IFN- induced apoptosis in B-lymphocytes. Indian J.Sci.Technol. 1 (3), 1-13. Cite ID: http://www.indjst.org.

  • Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR and Murty VV (1991) Chromosomal translocation t(15; 17) in acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66, 663-674.

  • Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub MP, Durand B, et al. (1992) Structure localization and transcriptional properties of two classes of retinoic acid receptor alpha afusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins. EMBO J. 11, 629-642.

  • Klimpel GR, Fleischmann WR and Klimpel KD (1982) Gamma interferon (IFN-?) and IFNa/ß suppress murine myeloid clony formation (CFU-C): magnitude of suppression is dependent upon level of colony-stimulating factor (CSF). J.Immunol.129, 76-80.

  • Koken MHM, Linares-Cruz G, Quignon F, Viron A, Chelib-Alix MK, Sobczak-Thepot J, et al. (1995) The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10, 1315-1324.

  • Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, et al. (1995) The acute promyelocytic leukemia-associated PML gene is induced by interferon. Oncogene 11, 871-876.

  • Liu H, Ding RS, Jiang SH, Yang JY., Cheng HQ, Lu DY, et al. (1996) Suppression of haematopoisis by sera from patients with aplastic anemia. Tokushima J.Experiment.Med. 43, 107-111.

  • Liu H, Mihara K, Kimura A, Tanaka K and Kamada N (1999) Induction of apoptosis in CD 34+ cells by sera from patients with aplastic anemia. Hiroshima J. Med.Sci. 48, 57-63.

  • Liu H, Tanaka K and Kamada N (2008) Differential expression of PML in 60Co ?-ray and ?-IFN- induced apoptosis in B-lymphocytes. Ind.J.Sci.Tachnol. 1 (3), 1-13. Domain site: http://www.indjst.org.

  • Maciejeuski JP, Seller C, Sato T, Anderson S and Young NS. (1995) Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. Brit. J. Haematol. 91, 245-252.

  • Maciejewski JP, Selleri C, Anderson S and Young NS (1995) Fas antigen expression on CD34+ human marrow cells is induced by interferon-? and tumor necrosis factor-aand potentates cytokine-mediated hematopoietic suppression in vitro. Blood 85, 3183-3190.

  • Mamus SW, Beck-Schroeder S and Zanjani ED (1985) Suppression of normal human erythropoiesis by gamma interferon in vitro: Role of monocytes and T-lymphocytes. J.Clinical Invest.75, 1496-1503.

  • Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, et al. (1997) FLICE is activated by association with the CD 95 death-inducing signaling complex (DISC). EMBO J. 16, 2794-2804.

  • Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, et al. (1995) Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 83, 883-889.

  • Nissen C (1991) The pathophophysiology of aplastic anemia. Seminar. in Hematol. 28, 313-318.

  • Pandolfi PP, Grignani F, Alcalay M, Mercarelli A, Biondi A, LoCoco F, et al. (1991) Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6, 1285-1292.

  • Philpott NJ, Scopes J, Marsch JCW and Gibson FM. (1995) Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Experimental Haematol. 23, 1642-1648.

  • Sabbe LJ, Haak HL, Te Velde J, Bradley-BA, de Bode L, Blom J and Van Rood JJ (1984) Immunological investigation in aplastic anemia patients. Acta Haematol. 71, 178-188.

  • Sen GC and Lengyel P (1992) The interferon system. A bird’s eye view of its biochemistry. J. Biol. Chemi. 267, 5017-5020.

  • Stadler M, Chelbi-Alix MK, Koken MHM, Venturini L, Lee C, Saib A, et al. (1995) Transcriptional induction of PML growth suppresor gene by interferons is mediated through an ISRE and GAS element. Oncogene 11, 2565-2573.

  • Terris B, Baldin V, Dubio S, Degot C, Flejou JF, Henin D, et al. (1995) PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res. 55, 1590-1597.

  • Tohda S, Suzuki T, Nagata K, Nara N and Aoki N (1990) Haematopoitic suppressing activity of gamma-interferon in serum and bone marrow of aplastic anemia patients. Acta Haematol. Jap. 53, 14-20.

  • Wang ZG, Ruggero D, Ronchettis S, Zhong S, Gaboli M, Rivi R et al. (1998) PML is essential for multiple apoptotic pathways. Nature Genet. 20, 266-272.

  • Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D and Pandolfi PP (2000) Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J. Experiment.Med.191, 631-638.

  • Zoumbos NC, Djeu JY and Young NS (1984) Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J. Immunol. 133, 769-774.


Abstract Views: 312

PDF Views: 81




  • Increased Expression of PML Protein in Lymphocytes Induced by Serum from Patients with Severe Aplastic Anemia

Abstract Views: 312  |  PDF Views: 81

Authors

Hong Liu
Department of Developmental Biology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Minamu-ku, Hiroshima, Japan
Kimio Tanaka
Department of Radiobiology, Institute for Environmental Sciences, Rokkasho , Aomori, Japan
Nanao Kamada
Hiroshima Atomic Bomb Relief Foundation, Asakita-ku, Hiroshima, Japan

Abstract


PML is essential for multiple apoptotic pathways and has an altered expression in human oncogenesis. However, the role of PML in regulating cell growth and apoptosis in aplastic anemia (AA) is still unclear. To investigate the involvement of PML in the pathogenesis of AA, the expression of PML protein and apoptosis in lymphocytes was measured with immunofluorescent staining after 24 hours incubation with serum of healthy individuals (controls, n=10) and patients with severe AA (SAA, n=10). After incubation with serum from SAA patients, PML protein was overexpressed both in peripheral lymphocytes from a normal donor and in a B cell line established from cells of the same individual. The normal lymphocytes contained a greater proportion of apoptotic cells after incubation with serum from SAA patients than serum from controls, which correlated to the serum-induced expression of PML. In addition, the induction of PML expression and apoptosis in lymphocytes by the serum was partly blocked by caspase 8 inhibitor, whereas no significant difference was found before and after caspase 3 inhibitor was added. These results indicate that some components contain of the serum of SAA patients, which was confirmed to γ-IFN by us, acts on lymphocytes not only to upregulate PML protein, but also to selectively activate caspase 8, causing apoptosis. This disregulation may play an important role in the pathogenesis of lymphocytopenia in aplastic anemia.

Keywords


Aplastic Anemia, PML Protein, Apoptosis, Caspase 3, Caspase 8

References





DOI: https://doi.org/10.17485/ijst%2F2008%2Fv1i4%2F29230